Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) drives advancements in life science research and molecular diagnostics through its innovative tools like the nCounter® Analysis System. This page aggregates official updates, financial disclosures, and critical developments impacting the company’s trajectory.
Access real-time announcements including product launches, patent litigation updates, and strategic partnerships. Investors gain insights into operational milestones, while researchers track applications in oncology, immunology, and neuroscience studies.
Discover coverage of earnings reports, regulatory filings, and scientific breakthroughs validated by 300+ peer-reviewed studies. Our neutral reporting ensures you stay informed without promotional bias.
Bookmark this page for streamlined access to NSTG’s evolving story. Check back regularly updated content to support data-driven decisions in biotech investing and research.
NanoString Technologies, Inc. (NASDAQ:NSTG) reported strong momentum in spatial biology, showing a 50% increase in orders YoY for over 105 instruments in Q4 2022. Revenue reached $34.4 million, with spatial biology contributing $14.8 million. The company recorded full-year revenues of $127.3 million. Notably, $40 million in CosMx orders is in backlog, positioning them for continued growth in 2023, with projected revenues between $170 million and $180 million. However, the company anticipates an adjusted EBITDA loss of $65 to $75 million. Cash reserves stood at $196.5 million as of year-end 2022.
NanoString Technologies (NASDAQ:NSTG) announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6-8, 2023. CEO Brad Gray will present on March 7, 2023, at 1:30 PM ET. Interested investors can access the live webcast via the company’s investor section at www.nanostring.com. The replay will be available one hour post-presentation and archived for 60 days. NanoString is recognized for its spatial biology tools, including the GeoMx Digital Spatial Profiler and the nCounter Analysis System, used widely in research, enhancing the understanding of biological processes.
NanoString Technologies, Inc. (NASDAQ:NSTG) will report its fourth quarter and fiscal year 2022 operating results on February 28, 2023, after market close. A conference call to discuss these results will be held at 4:30 PM ET the same day. Investors are encouraged to register in advance for the call via the provided link, which will also offer access to a replay starting at 7:30 PM ET on the reporting date and lasting until March 14, 2023. NanoString continues to innovate in spatial biology, with products like the GeoMx® Digital Spatial Profiler and CosMx™ Spatial Molecular Imager enhancing research capabilities.
NanoString Technologies has launched the Spatial Atlas of Human Anatomy (SAHA) initiative in collaboration with Weill Cornell Medicine. This ambitious project aims to create multicellular and single-cell maps of 30 healthy organs from a diverse adult population, encompassing over 250 million cells. The SAHA will develop a comprehensive database of spatial biology, offering insights into organ development and health.
Key technologies used include the GeoMx Digital Spatial Profiler and CosMx Spatial Molecular Imager, which will facilitate high-resolution analysis. The dataset will be made available publicly, promoting further research in spatial precision medicine.
NanoString Technologies (NASDAQ: NSTG) has released a new dataset generated by its CosMx™ Spatial Molecular Imager (SMI), showcasing its high sensitivity and specificity in analyzing liver tissue. The dataset includes over 800,000 single cells and approximately 700 million transcripts, highlighting the capability to detect an average of 1,150 transcripts per cell and 676 unique genes with more than 99% specificity. This technology enables comprehensive cell and tissue analysis in cancer research, particularly in hepatocellular carcinoma. Moreover, the data is available in an open-source format via the AtoMx™ Spatial Informatics Platform, enhancing research accessibility.
NanoString Technologies (NASDAQ:NSTG) reported strong Q4 results with over
NanoString Technologies (NASDAQ: NSTG) announced that its CosMx™ Spatial Molecular Imager was featured in National Geographic Magazine's January edition. The article discussed research from Wake Forest University, which utilized the CosMx SMI to examine brain tissue from Alzheimer’s patients, revealing critical insights into aging and cellular senescence. The CosMx SMI enables high-resolution imaging of over 1,000 RNA and 64 protein analytes, allowing researchers to create detailed cellular maps. This technology enhances research capabilities in cellular analysis and Alzheimer’s disease studies.
NanoString Technologies, Inc. (NASDAQ:NSTG) has announced its participation at the 41st Annual J.P. Morgan Healthcare Conference on January 11th, 2023, at 3:00pm PT. CEO Brad Gray will present during the event, which can be accessed via a live webcast on the company’s website. A replay will be available one hour post-presentation and archived for 60 days. NanoString is known for its innovative life science tools, including the GeoMx® Digital Spatial Profiler and CosMx™ Spatial Molecular Imager, enabling advanced research in spatial biology.
